Research on hypertension, also known as high blood pressure
Latest Research Highlights
From November 2025
The prevalence of concurrent diabetes and hyperlipidemia among adults with hypertension has nearly doubled, affecting over 21% of this population (ref: Lee doi.org/10.1016/j.jacc.2025.09.1607/)
Young-onset hypertension is associated with higher risks of cardiovascular and kidney diseases compared to late-onset hypertension, particularly in women (ref: Chow doi.org/10.2337/dc25-1839/)
Chronic kidney disease affects approximately 788 million adults globally, with only 12.3% awareness among those affected (ref: Global Burden of Disease Study 2023 doi.org/10.1016/S0140-6736(25)01853-7/)
The SARAH trial demonstrated that sacubitril-valsartan significantly reduces cardiotoxicity in patients undergoing chemotherapy, indicating its potential benefits for hypertensive patients (ref: Bonatto doi.org/10.1161/CIRCULATIONAHA.125.073322/)
Lifestyle interventions, such as DASH-patterned diets, can lead to significant reductions in blood pressure, although effects may not be sustained long-term (ref: Juraschek doi.org/10.1001/jama.2025.21112/)
Clonal hematopoiesis is enriched in patients with apparent treatment-resistant hypertension, suggesting a link to poorer treatment responses (ref: Lv doi.org/10.1038/s43587-025-01017-7/)
The presence of metabolic dysfunction-associated steatotic liver disease is associated with increased morbidity and mortality from cardiovascular disease (ref: Tilg doi.org/10.1001/jama.2025.19615/)
Hypertension is linked to neurovascular and cognitive dysfunction, with significant transcriptomic changes observed in affected brain regions (ref: Schaeffer doi.org/10.1016/j.neuron.2025.10.018/)